Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Shorter Survival in Right Hemisphere-Predominant Logopenic Progressive Aphasia
Aging, Dementia, and Behavioral Neurology
S14 - Behavioral and Cognitive Neurology (2:08 PM-2:16 PM)
002

LPA is a neurodegenerative language disorder characterized by hesitant spontaneous speech frequently accompanied by phonologic errors and impaired retention/repetition of long complex spoken stimuli. LPA is typically associated with strikingly asymmetrical atrophy/hypometabolism of the left lateral temporal lobe; few reports have described LPA associated with predominant right temporal lobe involvement (rLPA). Clinical characteristics of rLPA and differences from typical LPA represent a knowledge gap. 

To assess and compare demographic, clinical and neuroimaging characteristics of a cohort of patients with right versus left hemisphere-predominant logopenic progressive aphasia (LPA).

This is a case-control study utilizing 103 patients with LPA who were prospectively followed at Mayo Clinic and underwent an 18F-fluorodeoxyglucose (FDG)-PET scan.  Patients were classified as rLPA if metabolism in the right temporal lobe was ≥1 standard deviation lower than the left. Patients with rLPA were matched 1:3 to typical LPA based on degree of temporal lobe asymmetry and average lateral temporal lobe metabolism. SPM12 software was utilized to compare hypometabolism between rLPA and typical LPA.

Out of 103 LPA patients, 8 were classified as rLPA (7.8%) all being right-handed met criteria for crossed aphasia in dextrals syndrome, 4 (50%) were female. rLPA patients had milder aphasia with median Western Aphasia Battery-Aphasia Quotient (range) 88.6 (76-91.4) versus 74.4(33.5-95.5), p=0.0370, and less frequent phonologic errors, p=0.0151; however, rLPA had shorter survival than typical LPA: hazard ratio-6.23 (1.45-26.8), p=0.0139. No other differences in demographics, handedness, genetics, neurological or neuropsychological tests were observed. Compared to typical LPA, rLPA showed greater fronto-temporal hypometabolism of the non-dominant hemisphere on FDG-PET. Autopsy evaluation revealed similar distribution of pathologic findings in both groups Alzheimer’s disease being the most frequent pathology.

Right LPA besides milder aphasia is phenotypically indiscernible from typical LPA but appears to have shorter survival from symptom onset, possibly related to greater involvement of the non-dominant hemisphere.

Authors/Disclosures
Marina Buciuc, MD (MUSC)
PRESENTER
Dr. Buciuc has nothing to disclose.
Joseph Duffy No disclosure on file
Mary M. Machulda, PhD (Mayo Clinic) The institution of Dr. Machulda has received research support from NIH.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Nha Trang Thu Pham (Mayo Clinic) Nha Trang Thu Pham has received personal compensation for serving as an employee of Mayo Clinic.
No disclosure on file
Matthew Senjem (Mayo Clinic) Matthew Senjem has received stock or an ownership interest from Align Technology, Inc.. Matthew Senjem has received stock or an ownership interest from Inovio Biomedical Corp.. Matthew Senjem has received stock or an ownership interest from Johnson & Johnson. Matthew Senjem has received stock or an ownership interest from Mesa Laboratories, Inc.. Matthew Senjem has received stock or an ownership interest from Nvidia Inc.. Matthew Senjem has received stock or an ownership interest from LHC Group, Inc.. Matthew Senjem has received stock or an ownership interest from Natus Medical Incorporated. Matthew Senjem has received stock or an ownership interest from Varex Imaging Corporation. Matthew Senjem has received personal compensation in the range of $100,000-$499,999 for serving as a IT Technical Specialist II with Mayo Clinic.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Dennis W. Dickson, MD (Mayo Clinic) Dr. Dickson has nothing to disclose.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Jennifer Whitwell, PhD (Mayo Clinic) Dr. Whitwell has nothing to disclose.
Keith A. Josephs, Jr., MD, FAAN (Mayo Clinic) Dr. Josephs has nothing to disclose.